Indication
Tuberculous Meningitis
6 clinical trials
15 products
1 drug
Clinical trial
Comparative Evaluation of Intensified Short Course Regimen and Standard Regimen for Adults TB Meningitis : an Open-label Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2027-09-01
Product
RifampicinProduct
MoxifloxacinProduct
AspirinProduct
IsoniazidProduct
PyrazinamideProduct
SteroidProduct
HRZEProduct
HREClinical trial
A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous MeningitisStatus: Completed, Estimated PCD: 2022-04-30
Product
DexamethasoneClinical trial
Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)Status: Recruiting, Estimated PCD: 2025-09-01
Drug
AspirinProduct
PlaceboProduct
WHO TBM treatmentClinical trial
ANRS 12404 TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis: a Phase II, Multicenter, Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2025-06-01
Product
AdalimumabProduct
Intensified TBM treatmentClinical trial
A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase GenotypeStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
LinezolidClinical trial
A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis: Improved Management With Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM)Status: Recruiting, Estimated PCD: 2027-05-10
Product
Ethambutol